Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

A method of increasing a level of cyclic AMP, insulin, or incretin in a patient in need thereof, comprising administering to the patient a DPP-IV inhibitor and a compound selected from the group consisting of

• or a pharmaceutically acceptable salt thereof.